Daily non-political popular news in brief.
New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
02-02-2007 · EurekAlert!Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving Remicade (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75).
Read more »
Keywords: analyses, reinforce, efficacy, remicade, treatment, severe, psoriasis, analyse, psoriasi
« Previous | Next »
Similar news on "New analyses reinforce efficacy of Remicade in treatment of severe psoriasis":
- New findings show Enbrel significantly reduced levels of C-reactive protein
02-01-2008 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group. These results will be presented today at the American Academy of Dermatology Scientific Meeting in San Antonio, Texas.
Similar news · Read more »
- REMICADE-treated patients experienced substantial improvement in psoriasis in critical body regions
02-01-2008 · EurekAlert!
Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe psoriasis receiving REMICADE achieved a consistently high level of skin clearance in the head, trunk, lower and upper extremities as measured by the Psoriasis Area Severity Index. At week 10 of the analysis, 71 percent and 79 percent of patients receiving REMICADE 3 mg/kg or 5 mg/kg, respectively, achieved a at least a 75 percent improvement in psoriasis.
Similar news · Read more »
- Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis
02-02-2007 · EurekAlert!
Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving Remicade (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50.
Similar news · Read more »
- Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
02-02-2008 · EurekAlert!
One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
Similar news · Read more »
- Survey indicates people with chronic moderate to severe plaque psoriasis may be undertreated
02-02-2007 · EurekAlert!
The National Psoriasis Foundation and Amgen today released data, which show that nearly 40 percent of patients with chronic moderate to severe psoriasis are not currently receiving any treatment. Further, more than half of moderate to severe patients on treatment are not being treated in accordance with AAD guidelines, which state that patients diagnosed with chronic moderate to severe plaque psoriasis are candidates for phototherapy or systemic therapy, including biologic agents.
Similar news · Read more »
- Genetic analyis for personalizing of treatment of lung and colon cancer, certain sarcomas
03-05-2007 · EurekAlert!
Genetic analysis has enabled the personalising of the pharmaceutical treatment of patients with cancer, enhancing thereby therapeutic efficacy and minimising possible toxicity. In concrete, the Biotechnology Laboratory team at the University Hospital (University of Navarra), in close collaboration with the Pharmacogenomics laboratory at the Centre for Applied Medical Research of the same university, undertook these analyses predictive of responses to pharmaceutical drugs in patients with cancer of the lung, the colon and certain types of sarcoma.
Similar news · Read more »
- Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
05-17-2007 · EurekAlert!
Broncus Technologies Inc., today announced the start of its EASE (Exhale Airway Stents for Emphysema) Trial to explore an investigational procedure that may offer a new, minimally-invasive treatment option for millions of emphysema sufferers. The study focuses on a procedure called airway bypass that uses drug-eluting stents to reinforce new pathways in the lung for trapped air to escape. This in turn, may relieve severe emphysema symptoms such as shortness of breath.
Similar news · Read more »
- Safety analyses of clinical data for bifeprunox in patients with schizophrenia
03-30-2007 · EurekAlert!
Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week. Safety analyses suggest bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, was associated with a favorable weight and lipid profile, comparable with placebo. In addition, increases in weight occurred in patients receiving active references versus placebo.
Similar news · Read more »
- Scientists develop a fast system to detect metal concentrations in iron and steel industry workers
11-20-2007 · EurekAlert!
This method will analyze the levels of chromium, manganese and nickel in the employee's organism to determine possible work-related poisoning. Scientists from the University of Granada proposed to replace traditional blood and urine analyses with saliva and hair analyses, which are less invasive. A course at the Centro Mediterraneo at UGR on waste treatment discussed health problems caused by continuous exposure to different poisons.
Similar news · Read more »
- MERLIN TIMI-36 study provides new safety & efficacy data for unique anti-anginal therapy
03-27-2007 · EurekAlert!
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
Similar news · Read more »
